TradeFlare's AI research teams analysed RGNX on 10 market nights between June 25, 2026 and July 17, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 17, 2026 | BUY | $11.20 | — / — | -1.6% | +8.8% | The current market regime and the stock's fundamental and risk profiles do not support a buy recommendation. |
| July 9, 2026 | HOLD | $15.23 | — / — | -28.4% | -27.9% | FDA alignment on Navsunli BLA resubmission for MPS II. |
| July 8, 2026 | BUY | $15.02 | $18.02 / $12.77 | -19.4% | -31.1% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| July 7, 2026 | BUY | $13.28 | $14.78 / $11.29 | -18.2% | -31.4% | The post-earnings drift signal suggests a short-term upward momentum. |
| July 6, 2026 | BUY | $13.28 | $14.78 / $11.29 | -14.0% | -32.8% | The post-earnings drift signal suggests a short-term upward momentum. |
| July 3, 2026 | BUY | $13.28 | — / — | -14.0% | -32.8% | Post-earnings drift signal from scanner. |
| June 30, 2026 | BUY | $11.83 | $14.19 / $10.05 | +27.1% | -19.7% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| June 29, 2026 | BUY | $10.48 | — / — | +27.0% | -18.9% | The stock is currently at a resistance level, and the fundamental analysis is bearish, making a buy decision premature. |
| June 26, 2026 | BUY | $10.24 | $12.18 / $8.70 | +41.5% | -7.3% | The post-earnings drift signal suggests a short-to-medium term upward trend. |
| June 25, 2026 | BUY | $9.97 | — / — | +29.7% | -5.0% | Positive FDA sentiment regarding Navsunli gene therapy application. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.